1
|
Braun S, Paskaš S, Laube M, George S, Hofmann B, Lönnecke P, Steinhilber D, Pietzsch J, Mijatović S, Maksimović-Ivanić D, Hey-Hawkins E. Carborane-based Tebufelone Analogs and their Biological Evaluation In Vitro. ChemMedChem 2023:e202300206. [PMID: 37160667 DOI: 10.1002/cmdc.202300206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2023] [Revised: 05/03/2023] [Accepted: 05/09/2023] [Indexed: 05/11/2023]
Abstract
The presence of inflammatory mediators in the tumor microenvironment, such as cytokines, growth factors or eicosanoids, indicate cancer-related inflammatory processes. Targeting these inflammatory mediators and related signal pathways may offer a rational strategy for the treatment of cancer. This study focuses on the incorporation of metabolically stable, sterically demanding, and hydrophobic dicarba-closo-dodecaboranes (carboranes) into dual cyclooxygenase-2 (COX-2)/5-lipoxygenase (5-LO) inhibitors that are key enzymes in the biosynthesis of eicosanoids. The di-tert-butylphenol derivative tebufelone represents a selective dual COX-2/5-LO inhibitor. The incorporation of meta- or para-carborane into the tebufelone scaffold resulted in eight carborane-based tebufelone analogs that show no COX inhibition but 5-LO inhibitory activities in vitro. Cell viability studies on HT29 colon adenocarcinoma cells revealed that the observed antiproliferative effect of the para-carborane analogs of tebufelone is enhanced by structural modifications that include chain elongation in combination with introduction of a methylene spacer resulting in higher anticancer activity compared to tebufelone. Hence, this strategy proved to be a promising approach to design potent 5-LO inhibitors with potential application as cytostatic agents.
Collapse
Affiliation(s)
- Sebastian Braun
- Leipzig University: Universitat Leipzig, Institute of Inorganic Chemistry, GERMANY
| | - Svetlana Paskaš
- University of Belgrade: Univerzitet u Beogradu, Institute for Biological Research "Siniša Stanković", SERBIA
| | - Markus Laube
- HZDR: Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, GERMANY
| | - Sven George
- Universität Frankfurt am Main: Goethe-Universitat Frankfurt am Main, Institute of Pharmaceutical Chemistry, GERMANY
| | - Bettina Hofmann
- Universität Frankfurt am Main: Goethe-Universitat Frankfurt am Main, Institute of Pharmaceutical Chemistry, GERMANY
| | - Peter Lönnecke
- Leipzig University: Universitat Leipzig, Institute of Inorganic Chemistry, GERMANY
| | - Dieter Steinhilber
- Universität Frankfurt am Main: Goethe-Universitat Frankfurt am Main, Institute of Pharmaceutical Chemistry, GERMANY
| | - Jens Pietzsch
- HZDR: Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, GERMANY
| | - Sanja Mijatović
- University of Belgrade: Univerzitet u Beogradu, Institute for Biological Research "Siniša Stanković", SERBIA
| | - Danijela Maksimović-Ivanić
- University of Belgrade: Univerzitet u Beogradu, Institute for Biological Research "Siniša Stanković", SERBIA
| | - Evamarie Hey-Hawkins
- Leipzig University: Universitat Leipzig, Institute of Inorganic Chemistry, Johannisallee 29, 04103, Leipzig, GERMANY
| |
Collapse
|
2
|
Paskaš S, Murganić B, Kuhnert R, Hey-Hawkins E, Mijatović S, Maksimović-Ivanić D. Carborane-Based Analog of Rev-5901 Attenuates Growth of Colon Carcinoma In Vivo. Molecules 2022; 27:molecules27144503. [PMID: 35889376 PMCID: PMC9321230 DOI: 10.3390/molecules27144503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 07/08/2022] [Accepted: 07/08/2022] [Indexed: 11/16/2022] Open
Abstract
Lipoxygenases convert polyunsaturated fatty acids into biologically active metabolites such as inflammatory mediators—prostaglandins and leukotrienes. The inhibition of lipoxygenases is increasingly employed in the treatment of cancer. We evaluated the anticancer potential of two novel 5-lipoxygenase inhibitors, named CarbZDNaph and CarbZDChin, which are analogues of the commercially available inhibitor Rev-5901. The in vitro segment of this study was conducted on a mouse colorectal carcinoma cell line—CT26CL25. For an in vivo model, we induced tumors in BALB/c mice by the implantation of CT26CL25 cells, and we treated the animals with potential inhibitors. A 48 h treatment resulted in diminished cell viability. Calculated IC50 values (half-maximal inhibitory concentrations) were 25 μM, 15 μM and 30 μM for CarbZDNaph, CarbZDChin and Rev-5901, respectively. The detailed analysis of mechanism revealed an induction of caspase-dependent apoptosis and autophagy. In the presence of chloroquine, an autophagy inhibitor, we observed an increased mortality of cells, implying a cytoprotective role of autophagy. Our in vivo experiment reports tumor growth attenuation in animals treated with CarbZDChin. Compounds CarbZDNaph and Rev-5901 lacked an in vivo efficacy. The results presented in this study display a strong effect of compound CarbZDChin on malignant cell growth. Having in mind the important role of inflammation in cancer development, these results have a significant impact and are worthy of further evaluation.
Collapse
Affiliation(s)
- Svetlana Paskaš
- Department of Immunology, Institute for Biological Research “SinišaStanković”, Belgrade University, 11060 Belgrade, Serbia; (S.P.); (B.M.); (S.M.)
| | - Blagoje Murganić
- Department of Immunology, Institute for Biological Research “SinišaStanković”, Belgrade University, 11060 Belgrade, Serbia; (S.P.); (B.M.); (S.M.)
| | - Robert Kuhnert
- Institute of Inorganic Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, 04103 Leipzig, Germany; (R.K.); (E.H.-H.)
| | - Evamarie Hey-Hawkins
- Institute of Inorganic Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, 04103 Leipzig, Germany; (R.K.); (E.H.-H.)
| | - Sanja Mijatović
- Department of Immunology, Institute for Biological Research “SinišaStanković”, Belgrade University, 11060 Belgrade, Serbia; (S.P.); (B.M.); (S.M.)
| | - Danijela Maksimović-Ivanić
- Department of Immunology, Institute for Biological Research “SinišaStanković”, Belgrade University, 11060 Belgrade, Serbia; (S.P.); (B.M.); (S.M.)
- Correspondence: ; Tel.: +381-11-2078452
| |
Collapse
|
3
|
Buzharevski A, Paskaš S, Sárosi MB, Laube M, Lönnecke P, Neumann W, Murganić B, Mijatović S, Maksimović-Ivanić D, Pietzsch J, Hey-Hawkins E. Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. Sci Rep 2020; 10:4827. [PMID: 32179835 PMCID: PMC7076013 DOI: 10.1038/s41598-020-59059-3] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Accepted: 01/24/2020] [Indexed: 12/12/2022] Open
Abstract
Owing to the involvement of cyclooxygenase-2 (COX-2) in carcinogenesis, COX-2-selective inhibitors are increasingly studied for their potential cytotoxic properties. Moreover, the incorporation of carboranes in structures of established anti-inflammatory drugs can improve the potency and metabolic stability of the inhibitors. Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells. Furthermore, it was shown that the carborane-modified derivatives of rofecoxib showed different modes of action that were dependent on the cell type.
Collapse
Affiliation(s)
- Antonio Buzharevski
- Institut für Anorganische Chemie, Universität Leipzig, Johannisallee 29, D-04103, Leipzig, Germany
| | - Svetlana Paskaš
- Department of Immunology, Institute for Biological Research "Siniša Stanković"- National Institute of the Republic of Serbia", Belgrade University, Belgrade, Serbia
| | - Menyhárt-Botond Sárosi
- Institut für Anorganische Chemie, Universität Leipzig, Johannisallee 29, D-04103, Leipzig, Germany
| | - Markus Laube
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Radiopharmaceutical and Chemical Biology, Bautzner Landstrasse 400, D-01328, Dresden, Germany
| | - Peter Lönnecke
- Institut für Anorganische Chemie, Universität Leipzig, Johannisallee 29, D-04103, Leipzig, Germany
| | - Wilma Neumann
- Institut für Anorganische Chemie, Universität Leipzig, Johannisallee 29, D-04103, Leipzig, Germany
| | - Blagoje Murganić
- Department of Immunology, Institute for Biological Research "Siniša Stanković"- National Institute of the Republic of Serbia", Belgrade University, Belgrade, Serbia
| | - Sanja Mijatović
- Department of Immunology, Institute for Biological Research "Siniša Stanković"- National Institute of the Republic of Serbia", Belgrade University, Belgrade, Serbia
| | - Danijelа Maksimović-Ivanić
- Department of Immunology, Institute for Biological Research "Siniša Stanković"- National Institute of the Republic of Serbia", Belgrade University, Belgrade, Serbia
| | - Jens Pietzsch
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Department of Radiopharmaceutical and Chemical Biology, Bautzner Landstrasse 400, D-01328, Dresden, Germany
- Technische Universität Dresden, Faculty of Chemistry and Food Chemistry, Mommsenstrasse 4, D-01062, Dresden, Germany
| | - Evamarie Hey-Hawkins
- Institut für Anorganische Chemie, Universität Leipzig, Johannisallee 29, D-04103, Leipzig, Germany.
| |
Collapse
|
4
|
Paskaš S, Krajnović T, Basile MS, Dunđerović D, Cavalli E, Mangano K, Mammana S, Al-Abed Y, Nicoletti F, Mijatović S, Maksimović-Ivanić D. Senescence as a main mechanism of Ritonavir and Ritonavir-NO action against melanoma. Mol Carcinog 2019; 58:1362-1375. [PMID: 30997718 DOI: 10.1002/mc.23020] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2019] [Revised: 03/26/2019] [Accepted: 04/01/2019] [Indexed: 12/19/2022]
Abstract
The main focus of this study is exploring the effect and mechanism of two HIV-protease inhibitors: Ritonavir and Ritonavir-nitric oxide (Ritonavir-NO) on in vitro growth of melanoma cell lines. NO modification significantly improved the antitumor potential of Ritonavir, as the IC50 values of Ritonavir-NO were approximately two times lower than IC50 values of the parental compound. Our results showed for the first time, that both compounds induced senescence in primary and metastatic melanoma cell lines. This transformation was manifested as a change in cell morphology, enlargement of nuclei, increased cellular granulation, upregulation of β-galactosidase activity, lipofuscin granules appearance, higher production of reactive oxygen species and persistent inhibition of proliferation. The expression of p53, as one of the key regulators of senescence, was upregulated after 48 hours of Ritonavir-NO treatment only in metastatic B16F10 cells, ranking it as a late-response event. The development of senescent phenotype was consistent with the alteration of the cytoskeleton-as we observed diminished expression of vinculin, α-actin, and β-tubulin. Permanent inhibition of S6 protein by Ritonavir-NO, but not Ritonavir, could be responsible for a stronger antiproliferative potential of the NO-modified compound. Taken together, induction of senescent phenotype may provide an excellent platform for developing therapeutic approaches based on selective killing of senescent cells.
Collapse
Affiliation(s)
- Svetlana Paskaš
- Department of Immunology, Institute for Biological Research "Siniša Stanković", Belgrade University, Belgrade, Serbia
| | - Tamara Krajnović
- Department of Immunology, Institute for Biological Research "Siniša Stanković", Belgrade University, Belgrade, Serbia
| | - Maria S Basile
- Department of Immunology, Institute for Biological Research "Siniša Stanković", Belgrade University, Belgrade, Serbia.,Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Duško Dunđerović
- Institute of Pathology, School of Medicine, University of Belgrade, Belgrade, Serbia
| | - Eugenio Cavalli
- Department of Experimental Neurology, IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy
| | - Katia Mangano
- Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Santa Mammana
- Department of Experimental Neurology, IRCCS Centro Neurolesi "Bonino-Pulejo", Messina, Italy
| | - Yousef Al-Abed
- Center for Molecular Innovation, The Feinstein Institute for Medical Research, Manhasset, New York
| | - Ferdinando Nicoletti
- Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
| | - Sanja Mijatović
- Department of Immunology, Institute for Biological Research "Siniša Stanković", Belgrade University, Belgrade, Serbia
| | - Danijela Maksimović-Ivanić
- Department of Immunology, Institute for Biological Research "Siniša Stanković", Belgrade University, Belgrade, Serbia
| |
Collapse
|
5
|
Janković J, Tatić S, Božić V, Živaljević V, Cvejić D, Paskaš S. Inverse expression of caveolin-1 and EGFR in thyroid cancer patients. Hum Pathol 2016; 61:164-172. [PMID: 27818286 DOI: 10.1016/j.humpath.2016.10.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 09/23/2016] [Accepted: 10/14/2016] [Indexed: 01/21/2023]
Abstract
Cytological analysis of fine-needle aspiration (FNA) is the first step in evaluation of patients with nodular thyroid disease with the primary goal to exclude thyroid malignancy. Its improvement by combining cytology with molecular markers is still a matter of investigation. In this study, 2 molecular markers were used: caveolin-1 and epidermal growth factor receptor (EGFR), along with the well-established genetic marker BRAF V600E mutation. We set out to determine the expression signatures of EGFR and caveolin-1 in patients with thyroid malignancy as well as to determine their possible association with disease severity. In FNA biopsy samples (n=186), immunocytochemical expression of caveolin-1 and BRAF V600E mutation coincided with malignancy. The patients were sorted according to 3 parameters: final histopathological diagnosis, caveolin-1 expression, and BRAF V600E mutation status before measurement of EGFR mRNA expression. EGFR upregulation was detected in the group of patients with malignant diagnosis, no caveolin-1 expression, and wild-type BRAF. Spearman rank correlation yielded a statistically significant negative correlation of EGFR and caveolin-1. Double immunofluorescence confirmed colocalization and inverse expression of EGFR and caveolin-1. Our data demonstrated that EGFR overexpression is associated with malignancy but not with tumor aggressiveness. Furthermore, high-caveolin-1/low-EGFR cases were associated with an advanced pT status and had a greater degree of neoplastic infiltration than low-caveolin-1/high-EGFR cases. Combining caveolin-1 and BRAF V600E with EGFR might help in recognizing more aggressive thyroid lesions in a pool of relatively indolent tumors in FNA biopsies and thus be useful for early risk stratification of thyroid cancer patients.
Collapse
Affiliation(s)
- Jelena Janković
- Institute for the Application of Nuclear Energy-INEP, Department for Endocrinology and Radioimmunology, University of Belgrade, 11080 Belgrade, Serbia
| | - Svetislav Tatić
- Institute of Pathology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia
| | - Vesna Božić
- Clinical Center of Serbia, Department of Endocrine and Cardiovascular Pathology, 11000 Belgrade, Serbia
| | - Vladan Živaljević
- Center for Endocrine Surgery, Institute of Endocrinology, Diabetes and Diseases of Metabolism, University of Belgrade, 11000 Belgrade, Serbia
| | - Dubravka Cvejić
- Institute for the Application of Nuclear Energy-INEP, Department for Endocrinology and Radioimmunology, University of Belgrade, 11080 Belgrade, Serbia
| | - Svetlana Paskaš
- Institute for the Application of Nuclear Energy-INEP, Department for Endocrinology and Radioimmunology, University of Belgrade, 11080 Belgrade, Serbia.
| |
Collapse
|
6
|
Paskaš S, Janković J, Živaljević V, Tatić S, Božić V, Nikolić A, Radojković D, Savin S, Cvejić D. Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing. Cancer Cytopathol 2015; 123:471-9. [DOI: 10.1002/cncy.21554] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Revised: 04/02/2015] [Accepted: 04/02/2015] [Indexed: 01/21/2023]
Affiliation(s)
- Svetlana Paskaš
- Institute for the Application of Nuclear Energy; Department of Endocrinology and Radioimmunology; University of Belgrade; Belgrade Serbia
| | - Jelena Janković
- Institute for the Application of Nuclear Energy; Department of Endocrinology and Radioimmunology; University of Belgrade; Belgrade Serbia
| | - Vladan Živaljević
- Center for Endocrine Surgery, Institute of Endocrinology, Diabetes, and Diseases of Metabolism, University of Belgrade; Belgrade Serbia
| | - Svetislav Tatić
- Institute of Pathology, Medical Faculty, University of Belgrade; Belgrade Serbia
| | - Vesna Božić
- Department of Endocrine and Cardiovascular Pathology; Clinical Center of Serbia; Belgrade Serbia
| | - Aleksandra Nikolić
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade; Belgrade Serbia
| | - Dragica Radojković
- Institute of Molecular Genetics and Genetic Engineering, University of Belgrade; Belgrade Serbia
| | - Svetlana Savin
- Institute for the Application of Nuclear Energy; Department of Endocrinology and Radioimmunology; University of Belgrade; Belgrade Serbia
| | - Dubravka Cvejić
- Institute for the Application of Nuclear Energy; Department of Endocrinology and Radioimmunology; University of Belgrade; Belgrade Serbia
| |
Collapse
|
7
|
Paskaš S, Janković J, Marečko I, Išić Denčić T, Tatić S, Cvejić D, Savin S. Caveolin-1 Expression in Papillary Thyroid Carcinoma. Otolaryngol Head Neck Surg 2013; 150:201-9. [DOI: 10.1177/0194599813512781] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Objective We aimed to investigate the role of caveolin-1 in papillary thyroid carcinoma pathogenesis. Study Design Case series with chart review. Setting Institute for the Application of Nuclear Energy. Subjects and Methods We evaluated the expression of caveolin-1 in papillary thyroid carcinoma (PTC) by Western blot (WB) and compared the findings with immunohistochemical (IHC) expression of both epithelial and stromal caveolin-1 on the corresponding histological specimens. The results were related to clinicopathological features and BRAF mutation status. Results Caveolin-1 expression was found in malignant thyroid epithelium and more abundantly in tumor stroma but varied in both compartments within and between PTC subtypes. Caveolin-1 expression in the epithelium was more intense in classical PTC than in the other histological types. On the contrary, stromal caveolin-1 expression was stronger in the follicular, solid, and trabecular PTC variants than in classical PTC. Trends for down-regulation of caveolin-1 expression in epithelium and up-regulation in stroma from the classical via follicular to the solid variant were observed. The relation of WB and IHC results with clinicopathological parameters showed lower caveolin-1 tissue content in BRAF mutated tumors ( P < .05), a positive correlation of epithelial caveolin-1 expression with lymph node metastasis ( P < .05), and a negative association of stromal caveolin-1 expression with the degree of neoplastic infiltration and BRAF status. Conclusion Altered expression of caveolin-1 in the thyroid epithelial and stromal compartments may be involved in the pathogenesis of PTC. The potential clinical significance of caveolin-1 expression, as well as its relation to BRAF mutation status, deserves further investigation.
Collapse
Affiliation(s)
- Svetlana Paskaš
- Institute for the Application of Nuclear Energy–INEP, Department for Endocrinology and Immunoradiology, Belgrade, Serbia
| | - Jelena Janković
- Institute for the Application of Nuclear Energy–INEP, Department for Endocrinology and Immunoradiology, Belgrade, Serbia
| | - Ilona Marečko
- Institute for the Application of Nuclear Energy–INEP, Department for Endocrinology and Immunoradiology, Belgrade, Serbia
| | - Tijana Išić Denčić
- Institute for the Application of Nuclear Energy–INEP, Department for Endocrinology and Immunoradiology, Belgrade, Serbia
| | - Svetislav Tatić
- Institute of Pathology, Medical Faculty, University of Belgrade, Belgrade, Serbia
| | - Dubravka Cvejić
- Institute for the Application of Nuclear Energy–INEP, Department for Endocrinology and Immunoradiology, Belgrade, Serbia
| | - Svetlana Savin
- Institute for the Application of Nuclear Energy–INEP, Department for Endocrinology and Immunoradiology, Belgrade, Serbia
| |
Collapse
|
8
|
Janković J, Paskaš S, Marečko I, Božić V, Cvejić D, Savin S. Caveolin-1 expression in thyroid neoplasia spectrum: comparison of two commercial antibodies. Dis Markers 2013; 33:321-31. [PMID: 23023191 PMCID: PMC3810771 DOI: 10.3233/dma-2012-00934] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
We evaluated caveolin-1 expression in the human thyroid neoplasia spectrum with the aim of examining differences in expression as detected by two anti-caveolin-1 antibodies, and secondly, to investigate the association of caveolin-1 expression levels with aggressive papillary thyroid carcinoma (PTC). Immunohistochemical staining using sc894 or AV09019 antibodies revealed that caveolin-1 was generally overexpressed in the PTC group as a whole (classical and follicular variant) when compared to peritumoral tissue (PT), while it was not detected in about half of follicular thyroid carcinoma (FTC) and majority of follicular adenomas (FTA). Caveolin-1 expression decreased in the following order: clPTC, fvPTC, FTC, PT and FTA. The diagnostic accuracy of AV09019 was better than that of sc894 for discriminating: FTA from FTC, FTA or FTC from the follicular variant of PTC, total PTC from nonmalignant tissue, and malignant tumors from nonmalignant tissue. Spearman's analysis revealed positive correlations of caveolin-1 expression and extrathyroidal invasion (p< 0.05) in PTC for both antibodies. Additionally, AV09019 antibody correlated caveolin-1 upregulation with pathological T status. To conclude, as an immunohistochemical marker AV09019 antibody performed better than sc894 in distinguishing certain histotypes of thyroid tumors. In addition, increased expression of caveolin-1 may be considered as an indicator of papillary carcinoma progression.
Collapse
Affiliation(s)
- Jelena Janković
- Institute for the Application of Nuclear Energy - INEP, Department for Endocrinology and Immunoradiology, University of Belgrade, Serbia
| | | | | | | | | | | |
Collapse
|